Late-Breaking Data Showcase the Benefits of Abbott's Minimally Invasive Devices for People With Leaky Heart Valves

New data presented at Transcatheter Cardiovascular Therapeutics (TCT) 2023 from the TRILUMINATE pivotal trial confirm safety, effectiveness and improvements in quality of life when treating tricuspid regurgitation (a leaky valve) with TriClip, an investigational device in the US 

Related Keywords

San Francisco ,California ,United States ,Michael Dale ,Andreas Brieke ,David Adams ,Federico Asch ,Rebecca Hahn ,William Abraham ,Mount Sinai Health System ,York Heart Association ,Icahn School Of Medicine At Mount Sinai ,Cardiovascular Research Foundation ,Transcatheter Cardiovascular Therapeutics ,Kansas City Cardiomyopathy Questionnaire ,Icahn School ,Mount Sinai ,One Year Results From ,New York Heart Association ,Functional Class ,Transcatheter Tricuspid Valve Repair Content ,Tricuspid Valve Imaging ,Interventions Developing Hand In ,Tricuspid Device Clinical Trial Overview ,Ori Ben Yehuda ,Clip Device For Tricuspid Regurgitation Effective ,One Year ,Portico Content ,Treat Heart Failure ,Echocardiographic Findings ,